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Abstract
A large variation in neonatal herpes incidence is observed in USA
and Europe. Better knowledge of neonatal herpes epidemiology
is important to inform local prevention strategies. Between 2002
and 2008, the Swiss Paediatric Surveillance Unit reported
prospectively proven neonatal herpes simplex virus infections.
During the study period seven cases were declared, for an inci-
dence of 1.6/100 000 (95% CI 0.64–3.28/100 000) live births. This
is one of the lowest incidences of neonatal herpes reported.
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Introduction
Neonatal herpes (NH) results from vertical transmission of
herpes simplex virus type 1 (HSV-1) and HSV-2, usually
during the perinatal period but with a few cases acquired
through postnatal contact. Neonatal herpes results in sub-
stantial morbidity (including sequelae) and mortality [1]. The
risk of transmission varies between 30% during primary
maternal infections and <1% in recurrences [2].
The current approach for the prevention of NH is based
on caesarean section for mothers with clinically apparent
genital herpetic lesions at birth and acyclovir prophylaxis
during late pregnancy in women with a history of genital her-
pes to attempt to reduce the need for caesarean section [3].
However, the majority of NH infections occur in babies born
to mothers without a history of genital herpes, who have
subclinical primary infection [4]. To address this gap in NH
prevention, investigators have proposed to screen mothers
early during pregnancy by type-speciﬁc serology, to offer
counseling against genital transmission of HSV-1 or -2 and,
using virus detection by PCR at delivery, to identify babies
exposed during birth to HSV [5,6].
For poorly understood reasons, a large variation of NH
incidence is reported, ranging from 1.0 case per 2000 live
births in USA to 5.9 and 1.65 cases per 100 000 live births
in Canada and the British Isles respectively [1,7,8].
Hence, better knowledge of local NH epidemiology is the
key to designing local prevention strategies.
The objective of this study was to determine the inci-
dence, determinants, and morbidity and mortality rates of
proven NH in Switzerland.
Materials and Methods
Study design
Between 1 July 2002 and 30 June 2008, the Swiss Paediatric
Surveillance Unit, a national surveillance network that sends
a form each month to all participating medical centres to
prospectively report paediatric events, requested the report-
ing of NH.
The Lausanne University Hospital Research Ethics Com-
mittee approved this project.
A questionnaire regarding the patient data was sent to the
physicians who had reported cases of NH. The questionnaire
included demographic, microbiology, clinical data and HSV
history information of newborns and their mothers. The
Swiss Paediatric Surveillance Unit screened all case reports,
and each case was then assigned a study number.
To ensure conﬁdentiality, only initials were used on the
questionnaire and data were collected on an anonymous
basis for both the infant and mother. Completed question-
naires were sent to the principal investigator, who veriﬁed
that each report ﬁtted the case deﬁnition.
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After completion of the prospective surveillance, the par-
ticipating medical centres were asked to retrospectively
search in their medical record archives for the International
Statistical Classiﬁcation of Diseases and Related Health Prob-
lems (ICD-10) diagnostic codes—P35.2, A60.0 to A60.9,
B00.0 to B00.9, B02.0 to B02.9, L51.5 and B35.4—related to
NH infection from 0 to 30 days of life. These codes encom-
pass HSV-related conditions that might be used to describe
NH [9].
Current Swiss recommendations for the prevention of
NH are acyclovir treatment of clinical episodes and acyclovir
suppressive therapy during the last month of pregnancy in
women with a history of genital herpes. Caesarean section is
performed in women with clinical lesions present at delivery
[10].
Case deﬁnition
To be considered a case, the child had to be <30 days of age
at presentation, born between 1 July 2002 and 30 June 2008,
with: (i) laboratory-conﬁrmed HSV infection, established by
PCR, culture or HSV IgM serology and (ii) clinical signs or
symptoms compatible with (a) localized disease: disease lim-
ited to the skin, eyes and/or mouth; (b) disseminated: vis-
ceral organ involvement, with or without central nervous
system (CNS) or localized infection; (c) CNS disease: CNS
but no other visceral organ involvement.
Results
Thirty-seven clinics (including all ﬁve University Hospitals)
caring for all sick neonates in Switzerland participated in this
study. During the study period, seven cases of NH were
declared. These cases represent an incidence of 1.6/100 000
live births (95% CI 0.64–3.28/100 000, Poisson binomial dis-
tribution). The median of live births in Switzerland during
the period 2002–2008 was 73 082/year (range: 71 848–
76 691).
The retrospective medical record search, performed by
24 clinics including the ﬁve large University Hospitals, serving
about 68% of the birth cohort, identiﬁed all seven reported
cases and did not reveal any additional NH case.
We found a proportion of 14.3% (95% CI 0–49.2) skin,
eyes and/or mouth disease, 71.4% (95% CI 26.3–116.5) CNS
disease, and 14.3% (95% CI, 0–49.2) disseminated disease.
The incidence, clinical characteristics and outcome at the
moment of hospital discharge are detailed in Table 1.
At the time of delivery none of the woman presented any
genital lesion, and only one mother presented an oral lesion
(HSV-1). None of the mothers were receiving acyclovir
prophylaxis, and only one woman gave birth by caesarean
section. However, she did not have any lesions at the time
of delivery (HSV-1; Table 2).
Discussion
This incidence of NH in Switzerland is to our knowledge
one of the lowest reported in the literature. In international
comparison, the rate of NH found in Switzerland is similar
to rates reported elsewhere in Europe whereas the USA has
much higher incidence rates [1,8].
The severe outcome of NH in the majority of cases in a
relatively small country where most cases are seen in Uni-
versity Hospitals, and the paediatricians’ survey response
rate (the proportion of paediatricians reporting a possible
case of NH who completed the questionnaire) of 100%,
make under-diagnosis of new NH cases during the study per-
iod improbable. This fact was conﬁrmed by the results of the
retrospective search, which did not add any additional cases
and conﬁrmed all the cases reported in the prospective
study.
What might explain such a low incidence of NH in a
country where HSV-2 seroprevalence is similar to that in the
USA? [11]. First, national guidelines call for acyclovir prophy-
laxis during the last month of pregnancy in women with
known genital herpes, and for caesarean section in mothers
with herpetic lesions at labour [10]. We have no information
as to the compliance of obstetricians in Switzerland with
these guidelines. Second, maternal age has been demon-
strated to be inversely related with risk of NH, with moth-
ers <21 years of age having a several-fold higher risk of
transmitting HSV to their offspring [3]. This may reﬂect the
dramatically higher risk of vertical transmission during pri-
mary infection compared with reactivation [4]. Young moth-
ers are at a higher risk of primary infection as in the USA,
and the most rapid rise in HSV-2 seroprevalence is observed
before 30 years of age, particularly in African Americans
[12]. The average age of primiparous women in Switzerland
is increasing, approaching 30 years [13]. One can therefore
hypothesize that in Switzerland, the likelihood of primary
genital herpes infection in pregnant woman is lower than in
countries where higher numbers of young women have preg-
nancies. In fact, a relatively high maternal age (ﬁve women
out of seven were ‡30 years old) was observed in transmit-
ting mothers in Switzerland. In the absence of serological
data, we do not know how many of the transmitting moth-
ers were indeed experiencing primary infections.
Neonatal herpes in Switzerland was more frequently
caused by HSV-1 than by HSV-2. Consistent with this
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observation, recent reports showed a trend to an increase
of HSV-1 as an aetiological agent of genital herpes in other
countries [14,15]. No such studies have been conducted in
Switzerland. Indeed, HSV-1 genital infection also appears to
be acquired early in adult life [16,17].
One of the mothers of our series of cases who presented
an oral lesion at the time of delivery, and who was not pre-
scribed the preventative measures of acyclovir prophylaxis
or caesarean section, delivered a neonate that suffered a
CNS infection caused by HSV-1. This case could suggest that
preventative approaches should target HSV-1 (of oral as well
as genital origin), and not only HSV-2.
The low number of observed NH limits the interest of a
detailed analysis of case characteristics. However, our case
series is not inconsistent with the presentation as described
in larger series [18]. Of note, although four out of seven
infants had died or had mild to moderate impairment at the
time of discharge, we have no information as to their long-
term outcome.
Finally, one of the critical estimates to enter in a cost-
effectiveness analysis of NH prevention strategy is the
incidence of neonatal infection. For instance, Thung and
Grobman [19], when assessing the cost-effectiveness of
routine antenatal screening for maternal HSV-1 and HSV-2
antibodies, assumed an incidence of 18.28 neonatal infec-
tions/100 000 deliveries under standard care. Our data show
that the incidence in Switzerland with standard care is more
than one order of magnitude lower, suggesting that any such
preventative screening programme of asymptomatic pregnant
women is unlikely to be cost-effective in Switzerland, and
that it would be difﬁcult to convince clinicians to adopt such
a programme.
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TABLE 1. Incidence and characteristics of neonatal herpes cases in Switzerland during a 6-year observation period
Patients with neonatal HSV infection during the study period 7
Gestational age, median (range) 39 weeks (37.2–40.1)
Gender (male/female) 5/2
Weight at birth, median (range) 2850 g (2290–3450)
Age (days) at ﬁrst symptom, median (range) 5 (3–24)
Clinical infection HSV 1 HSV 2 Unknown
SEM disease 1 0 0
CNS disease 3 1 1
Disseminated disease 0 1 0
Outcome at the moment of hospital discharge HSV 1 HSV 2 Unknown
Normal 2 0 0
Mild impairment 1 0 0
Moderate impairment 0 1 1
Severe impairment 0 0 0
Death 0 1 0
Unknown 1 0 0
HSV, herpes simplex virus; SEM, skin, eye and mucous membrane; CNS, central nervous system.
TABLE 2. Characteristics of maternal herpes simplex virus infection
Patient
Age
(years)
Acyclovir
prophylaxis
during pregnancy
Vaginal
delivery
Maternal
history of oral herpes/oral
lesions at delivery
Maternal
history of genital
herpes/genital lesions at delivery
Swiss
recommendations
compliance
1 34 No Yes No/No No/No Yes
2 30 No Yes Yes/No Yes/No No
3 34 No Yes No/No No/No Yes
4 20 No Yes Yes/Yes No/No Yes
5 42 No Yes No/No No/No Yes
6 21 No Noa Yes/No No/No Yes
7 30 No Yes Yes/No No/No Yes
aCaesarean section (obstetrical reason).
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